198 related articles for article (PubMed ID: 15585441)
1. Atazanavir for the treatment of human immunodeficiency virus infection.
Busti AJ; Hall RG; Margolis DM
Pharmacotherapy; 2004 Dec; 24(12):1732-47. PubMed ID: 15585441
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.
Gatell J; Salmon-Ceron D; Lazzarin A; Van Wijngaerden E; Antunes F; Leen C; Horban A; Wirtz V; Odeshoo L; Van den Dungen M; Gruber C; Ledesma E;
Clin Infect Dis; 2007 Jun; 44(11):1484-92. PubMed ID: 17479947
[TBL] [Abstract][Full Text] [Related]
3. Atazanavir: new option for treatment of HIV infection.
Havlir DV; O'Marro SD
Clin Infect Dis; 2004 Jun; 38(11):1599-604. PubMed ID: 15156449
[TBL] [Abstract][Full Text] [Related]
4. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy of atazanavir in treatment-naive patients].
Moreno S; Hernández B; Dronda F
Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():9-13. PubMed ID: 20116611
[TBL] [Abstract][Full Text] [Related]
6. Atazanavir/ritonavir: a review of its use in HIV therapy.
von Hentig N
Drugs Today (Barc); 2008 Feb; 44(2):103-32. PubMed ID: 18389089
[TBL] [Abstract][Full Text] [Related]
7. Atazanavir.
Orrick JJ; Steinhart CR
Ann Pharmacother; 2004 Oct; 38(10):1664-74. PubMed ID: 15353575
[TBL] [Abstract][Full Text] [Related]
8. [Clinical utility of atazanavir].
Ribera Pascuet E; Curran A
Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():55-67. PubMed ID: 20116619
[TBL] [Abstract][Full Text] [Related]
9. Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study).
Pellegrin I; Breilh D; Ragnaud JM; Boucher S; Neau D; Fleury H; Schrive MH; Saux MC; Pellegrin JL; Lazaro E; Vray M
Antivir Ther; 2006; 11(4):421-9. PubMed ID: 16856615
[TBL] [Abstract][Full Text] [Related]
10. Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial.
Piketty C; Gérard L; Chazallon C; Marcelin AG; Clavel F; Taburet AM; Calvez V; Madelaine-Chambrin I; Molina JM; Aboulker JP; Girard PM;
Antivir Ther; 2006; 11(2):213-21. PubMed ID: 16640102
[TBL] [Abstract][Full Text] [Related]
11. Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatment-experienced patients.
Naeger LK; Struble KA
AIDS; 2006 Apr; 20(6):847-53. PubMed ID: 16549968
[TBL] [Abstract][Full Text] [Related]
12. Change to a once-daily combination including boosted atazanavir in HIV-1-infected children.
Macassa E; Delaugerre C; Teglas JP; Jullien V; Tréluyer JM; Veber F; Rouzioux C; Blanche S
Pediatr Infect Dis J; 2006 Sep; 25(9):809-14. PubMed ID: 16940839
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic properties and tolerability of bevirimat and atazanavir in healthy volunteers: an open-label, parallel-group study.
Martin DE; Galbraith H; Schettler J; Ellis C; Doto J
Clin Ther; 2008 Oct; 30(10):1794-805. PubMed ID: 19014835
[TBL] [Abstract][Full Text] [Related]
14. Clinically significant adverse events from a drug interaction between quetiapine and atazanavir-ritonavir in two patients.
Pollack TM; McCoy C; Stead W
Pharmacotherapy; 2009 Nov; 29(11):1386-91. PubMed ID: 19857154
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacology, efficacy and safety of atazanavir: a review.
Bentué-Ferrer D; Arvieux C; Tribut O; Ruffault A; Bellissant E
Expert Opin Drug Metab Toxicol; 2009 Nov; 5(11):1455-68. PubMed ID: 19863454
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.
Le Tiec C; Barrail A; Goujard C; Taburet AM
Clin Pharmacokinet; 2005; 44(10):1035-50. PubMed ID: 16176117
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes associated with concomitant use of atazanavir and proton pump inhibitors.
Sahloff EG; Duggan JM
Ann Pharmacother; 2006 Oct; 40(10):1731-6. PubMed ID: 16968825
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J
J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
[TBL] [Abstract][Full Text] [Related]
20. Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy.
Winston A; Bloch M; Carr A; Amin J; Mallon PW; Ray J; Marriott D; Cooper DA; Emery S
J Antimicrob Chemother; 2005 Aug; 56(2):380-7. PubMed ID: 15996972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
